Related Experiment Video
Updated: Jan 8, 2026
10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
33.2K
Ranibizumab biosimilar (Oceva) - real-world experience from India (RORE study)
Ashish Sharma1, Jay Sheth2, Chitaranjan Mishra3
1Lotus Eye Hospital and Institute, Coimbatore, India.
Expert Opinion on Biological Therapy
|December 18, 2025
Summary
Early real-world data indicate the ranibizumab biosimilar (Oceva) is safe and effective for eye conditions. Further long-term studies with more patients are recommended to confirm these promising findings.
Area of Science:
- Ophthalmology
- Pharmacology
- Clinical Research
Background:
- Evaluating early clinical outcomes of ranibizumab biosimilar (Oceva).
- Assessing safety and efficacy in real-world settings.
Purpose of the Study:
- To assess the early clinical outcomes, safety, and efficacy of ranibizumab biosimilar (Oceva).
Main Methods:
- Multicenter, retrospective, uncontrolled observational study.
- Data from 404 eyes receiving 742 intravitreal injections of Oceva.
- Included both treatment-naïve and previously treated eyes.
Main Results:
- Significant improvement in Best Corrected Visual Acuity (BCVA) from 0.87 to 0.59 LogMAR.
- Significant reduction in Central Foveal Thickness (CFT) from 406.8 µm to 306.5 µm.
- No serious ocular or systemic adverse events observed.
Conclusions:
- Ranibizumab biosimilar (Oceva) shows preliminary efficacy and safety in real-world use.
- Long-term data and larger populations are needed for stronger conclusions.
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
206
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
206
01:19Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
217
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
217
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
141
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
141
01:16Bioequivalence: Overview
1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
01:26Pharmaceutical Equivalents
171
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
171